SCHEMBL3261297

SCHEMBL3261297

CC(C)(C)NCc1nc(Cl)cc(-c2ccccc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ADORA1 P30542 5/20 0.41
HRH4 Q9H3N8 1/20 0.41
MAPT P10636 4/20 0.40
TDP1 Q9NUW8 2/20 0.40
PDCD1LG2 Q9BQ51 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
LMNA P02545 1/20 0.37
XDH P47989 1/20 0.36
TP53 P04637 1/20 0.36
AGTR1 P30556 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3229910 0.77 MEN1 (0.54) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL3419932 0.74 KDM4E (0.51) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL602093 0.69 KDM4E (0.61) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL3473073 0.68 TDP1 (0.76) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL413907 0.68 MEN1 (0.79) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL423874 0.68 KDM4E (0.66) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL3261298 0.68 MEN1 (0.51) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL23898440 0.67 MEN1 (0.48) KDM4EMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL13950567 0.67 SMN1; SMN2 (0.38) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL25068057 0.66 KDM4E (0.58) KDM4EHSP90AA1HSP90AB1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS GATAD2B, GATAD2A, RUNX1 KDM4E 377/4885HSP90AA1 4066/4885HSP90AB1 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.